Representative Experience

  • Represented BioLegend, a leading global provider of life science antibodies and reagents, in its $5.25 billion acquisition by PerkinElmer, Inc.
  • Represented the Cystic Fibrosis Foundation in a record-setting $3.3 billion sale of drug rights to Royalty Pharma following an intensive IP due diligence effort.
  • Achieved favorable arbitration ruling for the University of Kansas following years litigating a closely watched battle over inventorship credit on National Institute of Health-owned patents covering cancer drug formulations.

View More

  • Intellectual Property
    • Represented petitioner Medtronic in three inter partes review proceedings in which all challenged claims to a “Percutaneous Aortic Valve Replacement” were found unpatentable by the Patent Trial and Appeal Board, a ruling the Federal Circuit affirmed on appeal.
    • Pursued action for Invitae Corporation to have declared invalid genetic testing patents asserted by Myriad Genetics in a Utah MDL proceeding. Following extensive litigation, Myriad abandoned its patent enforcement efforts.
    • Defended Menicon Co. Ltd. in a Massachusetts district court patent infringement case and obtained a favorable resolution following a Markman hearing.
    • Represented a cord blood stem cell bank in a New Jersey trade secret and confidential information misappropriation action against a former manager who took confidential data to his national sales VP position with a direct competitor.
  • Transactions
    • Represented medical genetics testing company Invitae on an agreement to buy ArcherDX for up to $1.4 billion — creating a global leader in comprehensive cancer genetics and precision oncology.
    • Represented MediciNova, Inc., a specialty biopharmaceutical company, in the first Japanese IPO by a U.S. company that was not dual-listed in the United States. MediciNova sold $116.4 million of its common stock in its initial public offering on the Hercules market of the Osaka Stock Exchange.
    • Represented Chase Pharmaceuticals in equity financing by New Rhein Ventures, Edmond de Rothschild Investment Partners and Cipla (EU) Ltd.
    • Represented Opexa Therapeutics in its merger with Acer Therapeutics to focus on developing personalized immunotherapies.
    • Represented Genomic Health, Inc ., a genetic research company, in its $60 million initial public offering.
    • Represented Receptos, Inc. in its $72.8 million initial public offering.

Practice Area Highlights

  • Pillsbury advised Accelerated Infection Protectoin Technologies, Inc. in developing a breakthrough medication designed to reduce the spread of COVID-19. 

View More

  • Global Sourcing & Technology Transactions
    • Chambers Global and Chambers USA have repeatedly recognized Pillsbury's Outsourcing and Technology practices among the best globally. 
    • The Legal 500 U.S. named Pillsbury a top-ranked Tier 1 firm in Outsourcing. 
    • U.S. News—Best Lawyers consistently recognizes Pillsbury's Information Technology practice as Tier 1 nationwide in their "Best Law Firms" list.
    • International Association of Outsourcing Professionals (IAOP) selected Pillsbury as among the "World's Best Outsourcing Advisors" in their Global Outsourcing 100 list (2009-2021). 
  • Technology Acquisitions and Licensing
    • Chambers USA consistently ranks Pillsbury's Intellectual Property practice and individuals in Northern Virginia. 
    • The Legal 500 U.S. consistently ranks Pillsbury's Patent Prosecution practice nationally. 
    • U.S. News—Best Lawyers consistently recognizes Pillsbury's Intellectual Property practice as Tier 1 nationwide in their Best Law Firms list. 
    • Pillsbury's Intellectual Property practice was ranked among the best globally in the World Trademark Review 1000 (2021). 
    • Ranked in Washington, DC for litigation and prosecution and in Texas for litigation, prosecution and transactions by Intellectual Asset Management's IAM Patent 1000 (2020). 
    • Recognized by the Financial Times as one of North America's most innovative law firms as part of its 2020 Innovative Law Firms program. 
  • Emerging Growth & Venture Capital
    • Recognized by Chambers USA for startups and emerging growth nationally and for venture capital in California. 
    • U.S. News—Best Lawyers consistently recognizes Pillsbury's Corporate, Securities/Capital Markets, Venture Capital and M&A practices. 
    • Advised on 1,000+ public equity and debt securities offerings with an aggregate value exceeding $350 billion and $10 billion in venture financings since 2000 for technology and life sciences companies.
    • Led more than 80 IPOs, as issuer and as underwriter counsel, including the first internet IPO (Netcom), the first SaaS IPO (WebEx) and the first solar IPO (SunPower).
    • Team member Allison Leopold Tilley has been named one of The Recorder’s Women Leaders in Tech Law five years in a row.
    • From 2014 to 2018, The Daily Journal named team member Jorge del Calvo to its elite list of California’s top 100 lawyers.